TP53 and cancer: It is worth noting that a newly identified Skp2 inhibitor, with the use of other chemotherapeutic agents, has been shown to suppress Akt-mediated glycolysis and trigger p53-independent cellular senescence in multiple animal models to reduce cancer cell growth54.